Atypical Hemolytic Uremic Syndrome News and Research

RSS
Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros announces financial results for second quarter of 2013

Omeros announces financial results for second quarter of 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Combined complement mutations affect individuals' risk of aHUS and prognosis

Combined complement mutations affect individuals' risk of aHUS and prognosis

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Almac collaborates with Alexion for packaging and distribution of Soliris during German E. coli outbreak

Alexion third quarter total revenues increase to $204.0 million

Alexion third quarter total revenues increase to $204.0 million

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion second quarter net product sales of Soliris increase to $185.7 million

Alexion second quarter net product sales of Soliris increase to $185.7 million

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Genetic errors in women linked to increased risk of preeclampsia

Genetic errors in women linked to increased risk of preeclampsia

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment

Alexion announces results of eculizumab two open-label Phase 2 studies for aHUS treatment